Imaging as a biomarker: standards for change measurements in therapy NIST, Gaithersburg, MD.

Slides:

Advertisements

Similar presentations

FDA/Industry Workshop September, 19, 2003 Johnson & Johnson Pharmaceutical Research and Development L.L.C. 1 Uses and Abuses of (Adaptive) Randomization:

Advertisements

INTERNATIONAL HEALTHCARE STANDARDS LANDSCAPE

EHR stakeholder workshop – 11th October EHR integration for clinical research: toward new interaction models ? Isabelle de Zegher.

Paula M. Jacobs, Ph.D. SAIC Frederick Cancer Imaging Program/DCTD/NCI/NIH September 5, 2006 Phase 0 Trials in Oncologic Drug Development DCTD Phase 0 Workshop.

Data Acquisition Work Group Co-Chairs Paul E. Kinahan and Thomas L. Chenevert DAWG Milestone Chart Diffusion MRI Demonstration Project: Gradient.

Capturing and Reporting Adverse Events in Clinical Research

Copyright © 2006 Software Quality Research Laboratory DANSE Software Quality Assurance Tom Swain Software Quality Research Laboratory University of Tennessee.

Quality Assurance: Manufacturer & Clinical Aspects  Alan Cohen, M.S. DABR  Paul Naine, MSc. MIPEM  Jim Schewe, PhD, DABMP Accuray Incorporated Elekta.

Cancer Clinical Trials: The Basics. 2 What Are Cancer Clinical Trials? Research studies involving people Try to answer scientific questions and find better.

QIN-CBIIT Informatics Requirements for Clinical Decision Support and Precision Medicine QIN Meeting April th 2051 Joint CBIIT QIN Meeting Session.

INVESTIGATIONAL DRUG SERVICES IN THE HOSPITAL Sheree Miller, Pharm.D. University of Washington Medical Center

Radiation Dose Update REM Kevin O’Donnell Joel Chabriais Kevin O’Donnell Joel Chabriais.

 Quality & Safety Considerationsin Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy.

CALGB Informational Session June 22, 2007 David Hurd, MD Interim Chair Data Audit Committee.

DICOM INTERNATIONAL CONFERENCE & SEMINAR Oct 9-11, 2010 Rio de Janeiro, Brazil Collection and Management of Image Data for Clinical Trials Lawrence Tarbox.

NCI/NIST Perspective on IGI Research and Related Standards Laurence P. Clarke PhD, FAAPM; FISMRM NCI, DCTD, Cancer Imaging Program Detail (NIBIB) Guest.

Comprehensive Cancer Control Planning Telling New Jersey’s Story Peg Knight, RN, M.Ed. Executive Director Office of Cancer Control and Prevention New.

Building a Roadmap for Research IT John Brussolo Research IT Program Director September 6, 2012 © 2012 The Regents of the University of Michigan.

The Quantitative Imaging Network QIN Introductory Remarks Robert J. Nordstrom Larry Clarke Pushpa Tandon Yantian Zhang Huiming Zhang Lori Henderson March.

1CDISC 2002 RCRIM – Standard Domains Agenda NCI Presentation Standard Domains Working Group Goals Introduction to FDA Information Model (FIM) Discussion:

Slide - 1 Confidential. Slide - 2 Confidential Slide - 3 Confidential Interalgorithm Study using CT Images of synthetic nodules……….

THE DATA EXPLOSION: HOW CAN WE ACHIEVE INTEROPERABILITY F.David Rollo M.D., PhD., FACC, FACNP Chief Medical Officer Philips Medical Systems.

Panel Discussion Part I Methodology Ideas from adult MR brain segmentation are used in neonatal MR brain segmentation. However, additional challenges.

Study design P.Olliaro Nov04. Study designs: observational vs. experimental studies What happened?  Case-control study What’s happening?  Cross-sectional.

Morphometry BIRN Bruce Rosen, M.D. Ph.D.. Scientific Goal Methods –Multi-site MRI calibration, acquisition –Integrate advanced image analysis and visualization.

1 George Q. Mills, MD, MBA Vice President, Medical & Regulatory Relations Perceptive Informatics Workings of the SNM Clinical Trials Network Centralized.

NCI Workshop Bethesda, MD May 3 – 4, 2012 Next-Generation DNA Sequencing as a Tool for Clinical Decision-making in Cancer Patient Management.

May 19-20, Quantitation, both single point and longitudinal*, of tumor metabolism via FDG-PET/CT that can be used practically and efficiently as.

Overview of Formal Methods. Topics Introduction and terminology FM and Software Engineering Applications of FM Propositional and Predicate Logic Program.

ARGOS Global Conference: Parallel Session 1 – VPH May 11 th, 2011 Budapest.

1 Inter-observer Agreement of The Response To Therapy AssessmentInter-observer Agreement of The Response To Therapy Assessment in Advanced Lung Cancer.

Organization and guideline development April 2010 ACCC The Netherlands.

HYGIA: Design and Application of New Techniques of Artificial Intelligence for the Acquisition and Use of Represented Medical Knowledge as Care Pathways.

CRIX: toward a secure, standards-based, clinical research information exchange.

The SNM Centralized IND & Clinical Trials Network Enabling Implementation Investigational & Approved PET Imaging in Multicenter Clinical Trials George.

Building Clinical Infrastructure and Expert Support Michael Steinberg, MD, FACR ULAAC Disparity Project Centinela/Freeman Health System.

Cancer Centers In Clinical Trials Sandrine Marreaud Head of Medical Department.

Radiological Physics Center David Followill, Ph.D. and RPC Staff.

Scanner Validation via the SNM Clinical Trials Network Phantom Program Paul E. Christian Molecular Imaging Program Huntsman Cancer Institute University.

Vanderbilt Sports Medicine Chapter 5: Therapy, Part 2 Thomas F. Byars Evidence-Based Medicine How to Practice and Teach EBM.

Imaging as a biomarker: standards for change measurements in therapy NIST, Gaithersburg, MD.

The SNM Centralized IND & Clinical Trials Network Enabling Implementation Investigational & Approved PET Imaging in Large Multicenter Clinical Trials George.

CTSA Imaging Working Group Coordinated by: RSNA (Radiologic Society of North America) DTRI (Duke Translational Research Institute)

MATT REID JULY 28, 2014 CCDA Usability and Interoperability.

Design of Micro-arrays Lecture Topic 6. Experimental design Proper experimental design is needed to ensure that questions of interest can be answered.

Digital Reference Object Subcommittee Goals 1.Build a common reference DICOM test object (digital reference object or DRO) that can be generated by each.

$100 $200 $400 $500 $300 $100 $200 $400 $500 $300 $100 $200 $400 $500 $300 $100 $200 $400 $500 $300 $100 $200 $400 $500 $300 Terms Clinical Trial Facts.

Progress of the SNM Clinical Trials Network Michael Graham, PhD, MD Clinical Trials Network Co-Chair SNM President 1.

Comparative Effectiveness Research : Rethinking Therapeutic Evaluation in Chronic Diseases Ph Ravaud.

1 Imaging Community Critical Need #1: Standardized and Harmonized Multisite Imaging George Q. Mills, MD, MBA Vice President, Medical & Regulatory Relations.

Introduction to Research. Purpose of Research Evidence-based practice Validate clinical practice through scientific inquiry Scientific rational must exist.

FDA Standards Development and Implementation Randy Levin, M.D. Director, Office of Information Management Center for Drug Evaluation and Research Food.

QIBA DCE-MRI Technical Committee Jeffrey L. Evelhoch, PhD Executive Director, Medical Sciences Head, Imaging Sciences MEDICAL IMAGING CONTINUUM Path Forward.

CTEP Visiting Physician Externship Coordinator: Igor Espinoza-Delgado, M.D. NCI CTEP Investigational Drug Branch

CARS Special Session on IHE Integrating the Healthcare Enterprise – An Industry Perspective – Frequently Asked Questions Geert Claeys– AGFA (Co-Chairman.

Radiation Therapy Trials - Quality Assurance:  patient safety  adherence to protocol constraints  uniformity of patient treatments  efficient review.

1 The Data Explosion How can we achieve interoperability? James Williams Siemens Corporate Research Princeton, NJ.

SpiroSmart: Development of a mobile phone-based spirometer with feedback capability J. Stout, S. Patel, EC Larson, M. Goel, D. Burges, M. Rosenfeld.

June 28-29, 2005IHE Interoperability Workshop 1 Integrating the Healthcare Enterprise Teaching File and Clinical Trial Export John Perry Fujifilm Medical.

Cancer Clinical Trials Office Clinical Trials & Research Training Oct2014.

CLINICAL TRIALS.

Integrating the Healthcare Enterprise

IAEA E-learning Program

USING NATIONAL GUIDELINES FOR SCREENING, TREATMENT, AND FOLLOW-UP

EHR Integration Making Research Efficient

Richard Cavanagh Director, Special Programs Office

Incentives for Interoperable EHR Adoption…. …

The Learning Healthcare System: Create, Implement and Maintain

Comments on design and sequence of biomarker studies

Digital Reference Object Subcommittee

Presentation transcript:

Imaging as a biomarker: standards for change measurements in therapy NIST, Gaithersburg, MD

Workshop « Imaging as Biomarker »  General issue: Imaging use for Clinical trials  Organized by NIST  Supported by:  Sponsoring organization: NIH, NCI (Larry Clarke)  FDA  Pharmaceutical industry: PhRMA, big labs  Normalization structures: NIST, NEMA  Professional societies: RSNA, AAPM, SNM, ISMRM, SPIE  Vendors: Siemens, GE, Philips  General issue: Imaging use for Clinical trials  Organized by NIST  Supported by:  Sponsoring organization: NIH, NCI (Larry Clarke)  FDA  Pharmaceutical industry: PhRMA, big labs  Normalization structures: NIST, NEMA  Professional societies: RSNA, AAPM, SNM, ISMRM, SPIE  Vendors: Siemens, GE, Philips

The issues (1/2)  Use of imaging to evaluate new treatment efficiency:  Not only a subjective reading of images  But, more and more objective measurements with “quantitative” methods  Examples : Alzheimer desease, lung cancer, arthrosis…  Low efficiency statement of clinical trials  Longs, expensives, and often… no positive result!  …  Use of imaging to evaluate new treatment efficiency:  Not only a subjective reading of images  But, more and more objective measurements with “quantitative” methods  Examples : Alzheimer desease, lung cancer, arthrosis…  Low efficiency statement of clinical trials  Longs, expensives, and often… no positive result!  …

The issues (2/2)  Main reasons:  Too often, mediocre quality of image data  No quantitative  Reproducibility issues (intra system and inter systems)  Acquisition protocols non respected → lot of cases are non usable  Data processing differs between different site ( → “site” effect)  Too subjective  Not enough automated  Insufficient quality of clinical data associated  “Local” semantic for clinical information  Resulting bias amplify intrinsic variability of the phenomena  → increase of the necessary number of cases  Data management cost  Because support tools needs to be rebuild case by case  Data cannot be re-used  Despite the politic of sponsoring organizations (dissemination plan)  No sharing infrastructure  Main reasons:  Too often, mediocre quality of image data  No quantitative  Reproducibility issues (intra system and inter systems)  Acquisition protocols non respected → lot of cases are non usable  Data processing differs between different site ( → “site” effect)  Too subjective  Not enough automated  Insufficient quality of clinical data associated  “Local” semantic for clinical information  Resulting bias amplify intrinsic variability of the phenomena  → increase of the necessary number of cases  Data management cost  Because support tools needs to be rebuild case by case  Data cannot be re-used  Despite the politic of sponsoring organizations (dissemination plan)  No sharing infrastructure

Solution components, standard based (1/2)  Standard phantoms to calibrate imaging systems  Standard study protocols  To be really identical between machines (patient preparation, image acquisition, pre-processing and applied corrections, reconstruction…)  Standard procedures (guidelines) to manage clinical trials  good comprehension of protocols, physician and technologists education, quality assurance  Meta data and clinical data standardization  Need the use of normalized terminologies, ontologies…  Standard phantoms to calibrate imaging systems  Standard study protocols  To be really identical between machines (patient preparation, image acquisition, pre-processing and applied corrections, reconstruction…)  Standard procedures (guidelines) to manage clinical trials  good comprehension of protocols, physician and technologists education, quality assurance  Meta data and clinical data standardization  Need the use of normalized terminologies, ontologies…

Solution components, standard based (2/2)  Management tools adapted to the data and processing management  Scientific calculation  Step sequencing (including quality assurance)  Providing the required traceability  Compatibility issues with current PACS (regarding image management)  Reference implementation (open source shared tools)  Standard processing tools (that can be shared)  Open source  Plug-in or services remotely executable  Standard data  Anatomical atlases  Reference data (e.g. healthy populations )  Management tools adapted to the data and processing management  Scientific calculation  Step sequencing (including quality assurance)  Providing the required traceability  Compatibility issues with current PACS (regarding image management)  Reference implementation (open source shared tools)  Standard processing tools (that can be shared)  Open source  Plug-in or services remotely executable  Standard data  Anatomical atlases  Reference data (e.g. healthy populations )

Needs for the future  Medical  No more and less than tomorrow treatments for numerous pathologies  Vendors  Pharmaceutical industry, decrease of validation costs for new medication  Imaging systems industry  New generations of systems. Economical model.  Sharing / interoperability of processing tools  Scientific  Validation of processing and image quantification tools  Diffusion and re-use of tools  Medical  No more and less than tomorrow treatments for numerous pathologies  Vendors  Pharmaceutical industry, decrease of validation costs for new medication  Imaging systems industry  New generations of systems. Economical model.  Sharing / interoperability of processing tools  Scientific  Validation of processing and image quantification tools  Diffusion and re-use of tools

What happened since the NIST workshop ?  The Gil Jost (RSNA), Larry Clarke (NCI) and Michael Vannier (University of Chicago) propositions were well received in France and Europe  SFR and ESR decided to join RSNA and NCI in an international initiative on biomarkers  At RSNA meeting, Guy Frija (ESR) and Philippe Grenier (SFR) met Gil Jost to discuss on this topic.  SFR will launch a biomarkers working group.  The Gil Jost (RSNA), Larry Clarke (NCI) and Michael Vannier (University of Chicago) propositions were well received in France and Europe  SFR and ESR decided to join RSNA and NCI in an international initiative on biomarkers  At RSNA meeting, Guy Frija (ESR) and Philippe Grenier (SFR) met Gil Jost to discuss on this topic.  SFR will launch a biomarkers working group.